Study disputes effectiveness of anticoagulant drug

Organisation: Position: Deadline Date: Location:

[b]Bivalirudin[/b], a newer anticoagulant, has been touted as being as effective as generic heparin as an options for patients undergoing coronary stenting for ischemic heart disease, but with nearly half the rate of bleeding. However, [s]Science Newsline[/s] reports that several studies have hinted that, compared with heparin, bivalirudin-based regimens might not protect as well against recurrent heart attacks and might increase the risk of stents clotting off. Researchers from [b]Brigham and Women’s Hospital[/b] analysed all of the previous trials to date and found that, compared with heparin-based regimens, bivalirudin-based regimens increased the risk of heart attack and stent thrombosis. Bivalirudin-based regimens decreased the risk of bleeding, but by how much depended on whether other blood thinners were used more with heparin than with bivalirudin.

Full Science Newsline report
The Lancet article summary

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.